Age-related macular degeneration
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries and its prevalence and incidence is likely to increase dramatically with the aging of the population. 1 The exudative form of AMD, although less common than the atrophic form, is more threatening to vision: 90% of those with severe visual loss due to AMD suffer from the exudative type.
The main pathological feature that characterizes the exudative form of AMD is choroidal neovascularization (CNV). Although many aspects of the molecular pathogenesis of exudative AMD have not yet been elucidated, experimental and clinical evidence has demonstrated that vascular endothelial growth factor A (VEGF-A) plays a central role in promoting CNV. [2] [3] [4] Intravitreal injection of anti-VEGF-A agents is the current treatment of choice for neovascular AMD (nAMD), and five molecules have been introduced into clinical practice since 2004 (bevacizumab, pegaptanib, ranibizumab, aflibercept and a molecule newly approved for the Chinese market, conbercept). This has brought about dramatic changes in the management of the pathology, but the challenges related to the treatment of nAMD remain numerous. Thus, there is a need for efforts to investigate new areas involved in the pathophysiology of neovascularization (NV) of the eye. Many fields of interest seem to be promising: among them, research regarding new molecular targets involved in the neoangiogenic pathway, together with VEGF-A, would appear to have the potential to bring significant therapeutic improvements in the near future.
Neoangiogenesis in age-related macular degeneration
Neoangiogenesis is a physiological mechanism involved in many embryonic and adult life processes, such as wound healing, blood vessels reforming during menstruation, placenta formation, etc. Neoangiogenesis may also occur as an unfavourable phenomenon, as is the case, for example, with tumor growth, or in physiologically avascular tissues, such as the cornea, vitreous body or the macular region of the retina. Two major types of ocular NV affect the retina: retinal NV, which is the pathogenetic basis for proliferative diabetic retinopathy, retinal vein occlusions, and retinopathy of prematurity; and subretinal or CNV. 5 Subretinal and CNV occur in diseases of the outer retina and Bruch's membrane, the most prevalent being nAMD. There is a considerable overlap in the vasoactive molecules involved in retinal and CNV, as both result from a functional dominance of angiogenic factors over antiangiogenic/angiostatic factors, regardless of whether the primary event is an increase in angiogenic activity or a decrease in antiangiogenic activity. Although it has not been clearly demonstrated, hypoxia is probably the common primum movens: it provokes the expression of hypoxiainducible factor-1α (HIF-1α), which, after binding with HIF-1β, becomes an active molecule (HIF-1) capable of promoting the expression of several genes 6 including VEGF-A, platelet-derived growth factor (PDGF), stromal cell-derived growth factor-1 (SDF-1), and placental growth factor (PIGF).
Challenges to current therapeutic strategies
Despite the success of anti-VEGF-A drugs, modifications and improvements in the management of nAMD are still warranted in relation to several aspects.
Treatment regimens and followup frequency
The treatment of nAMD requires repeated injections and long-term, frequent follow-up. Different treatment schedules have been designed in order to reduce the treatment burden. The most commonly used ones are the pro-re-nata (PRN) and the treat-and-extend regimens. [7] [8] Analysis of the CATT and the IVAN trials shows that monthly administration has a better effect on vision than an as needed approach, 9-10 although clinicians have not yet reached a consensus regarding the best treatment regimen. Nevertheless, there is evidence that shorter injection intervals lead to better visual outcome and steady anatomic improvements. The high costs of frequent anti-VEGF-A drug injections and of a strict regimen of follow-up visits render the treatment of nAMD financially burdensome.
Complications
Although it is widespread as a technique, the practice of intravitreal injection is not completely free of complications. The intravitreal injection of anti-VEGF-A drugs is related to many adverse events, such as subconjunctival hemorrhages, retinal tears and retinal detachments, vitreous hemorrhages, retinal vascular occlusion, increase of intraocular pressure, cataract, tachyphylaxis, intraocular inflammation and endophthalmitis. [11] [12] [13] [14] Blockage of the VEGF-A pathway itself seems to have potentially negative effects on retinal trophism, due to the role that VEGF-A may play in the maintenance of the choriocapillaris, Müller cells and photoreceptors. 15 Long-term intravitreal injection of anti-VEGF-A drugs has been correlated with the possible progression of areas of geographic atrophy in patients with nAMD.
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Visual loss despite anti-vascular endothelial growth factor A therapy
Inadequate response to anti-VEGF-A drugs is, unfortunately, a common finding and much CNV remains active despite a protocol of frequent and timely injections. The SEVEN-UP study showed that, approximately 7 years after ranibizumab therapy in the ANCHOR and MARINA trials, one third of patients demonstrated good visual outcomes, whereas another third had poor visual outcomes. 17 The causes for resistance to anti-VEGF-A therapy are hypothesized to be various: mechanisms of tolerance, tachyphylaxis, compensation by other angiogenic factors, changes in vascular architecture, sustained activation of the complement system, as well as inflammatory response, misdiagnosis and genetic variants. 18 
Future directions: a focus on new molecular targets
Considering the unresolved problems connected to the current management of patients affected by nAMD, many efforts are being made worldwide in order to design new therapeutic approaches to this multifactorial pathology. It is not the aim of this contribution to discuss new drug delivery methods, which nonetheless represent a very promising field of interest and a valuable potential source of improvement for the current therapeutic strategies. The purpose of this review is to briefly review the promising new molecular targets for neoangiogenesis (Figure 1 ), inflammation or fibrosis inhibition (Figure 2 ), that could represent a potential resource in the treatment of nAMD and the related drugs in various stages of development ( .0-mg RTH258 doses compared to ranibizumab, and an increase of 30 days in the median time to retreatment for the 6.0-mg dose. 22 A phase III clinical trial comparing the efficacy and safety of RTH258 versus aflibercept in subjects with nAMD is ongoing (ClinicalTrials.gov identifier: NCT02307682).
body. S1P is a bioactive lipid mediator whose biological activities are moderated by the surface receptors found on endothelial cells. Retinal pigment epithelium (RPE) may release and store S1P in the retina and could contribute to the pathological angiogenesis, vascular permeability, fibrosis and inflammatory responses associated with nAMD. 23 Sonepcizumab, a monoclonal antibody that selectively binds to S1P, was evaluated in animal models with oxygeninduced ischemic retinopathy and was found to cause a decreased inflow of macrophages into the retina, the suppression of retinal NV, and reduced CNV after laser disruption of Bruch's membrane. 23 AMD. The preliminary safety data of these two compounds were encouraging, but they failed to meet key efficacy parameters in further studies. 24 
Platelet-derived growth factor inhibition
In vitro studies have demonstrated the role of PDGF in the process of angiogenesis. 25 It has been shown to promote the migration and proliferation of endothelial cells, as well as an increase in the recruitment of pericytes, which have been demonstrated to play a central role in protecting the endothelial cells against VEGF-A inhibition. 26 The involvement of PDGF in the ocular NV process has been demonstrated 27 and seems to be related to the entry of platelets and monocytes into the vitreous and subretinal space upon injury to the blood-retina barrier, with subsequent platelet aggregation and PDGF discharge. Interleukins such as IL-1 and TGF-β released from activated macrophages may cause further synthesis and release of PDGF. 
Tyrosine kinase inhibition
Since, as suggested by recent research, the activity of VEGF-A and other angiogenic factors is regulated by tyrosine kinases, kinase inhibitors may be used to target VEGFRs. The high homology between VEGFRs and PDGFRs allows many kinase inhibitors to simultaneously block both. 28 -Axitinib. Axitinib is a multi-receptor tyrosine kinase inhibitor that has marked inhibitory effects on VEGFR2, PDGFR-β and c-KIT receptors. Axitinib is currently approved for use in advanced human renal cell carcinoma. Because of its anti-VEGFR and anti-PDGFR-β action, its use in nAMD treatment has been suggested. It recently showed good efficacy at a low dose in a laser-induced CNV model in rats. 29 -Pazopanib. Pazopanib (GlaxoSmithKline, Brentford, UK) (GW786034) is a small molecule that has been investigated as an eye drop in CNV, due to its ability to act as an inhibitor of VEGFRs 1, 2, and 3; PDGF-α and β; and the stem cell factor receptor c-KIT. [30] [31] [32] [33] [34] A multi-country, randomized, double-masked, dose-ranging study phase IIb clinical trial was completed in 2015. It demonstrated the inferiority of daily pazopanib eye drops compared to intravitreal injection of ranibizumab in the treatment of nAMD. FGFR1-3, TIE2 , and of the autophosphorylation of other pro-angiogenic tyrosine kinase receptors. This molecule was initially investigated as an oral antineoplastic agent but showed poor results. Subsequently it was adopted as an eye drop for AMD and diabetic retinopathy, since it is a small molecule with high permeability and has the ability to concentrate high doses in the active form at the posterior pole. Phase I/II studies are currently ongoing (ClinicalTrials.gov identifier: NCT02022540). -Sorafenib. Sorafenib is an oral MKI whose antiangiogenic action inhibits VEGFR-1, -2, and -3, as well as PDGFR-β, RAF kinase and c-KIT. 37 In a study using a mouse model of CNV, sorafenib showed the ability to decrease the extent of CNV in a dose-dependent manner. 38 In two case reports, sorafenib was administered orally in combination with intravitreal anti-VEGF-A treatment and all patients appeared to gain some benefit. [39] [40] Pigment epithelium-derived factor PEDF is a cell survival factor secreted by the RPE, widely expressed in the central and peripheral nervous system, 41, 42 and apparently an endogenous inhibitor of angiogenesis in the eye. 43 A critical balance appears to exist between PEDF and VEGF-A, with PEDF counteracting the angiogenic potential of VEGF-A. A physiological decrease in PEDF occurring in the elderly may disrupt this balance and create a permissive environment for the formation of CNV in AMD. 44 PEDF gene polymorphisms may also contribute to AMD. 45 -ATG003. PEDF protein expression has been found to be decreased in RPE from smoker patients with AMD compared to controls. 46 It has also been reported that nicotine, a potent angiogenic agent, increased the VEGF-A/PEDF ratio in the RPE through nicotinic acetylcholine receptor (nAchR (GenVec, Inc., Gaithersburg, MD, USA), seems to allow the expression of large amounts of PEDF in the target tissue and inhibit ocular NV in murine AMD models. 48 Intravitreal injection of AdGVPEDF.11D results in the local production of PEDF. A phase I single-dose trial enrolled 28 patients with severe nAMD. 49 This clinical study suggested that antiangiogenic activity may last for up to 6 months after a single intravitreous injection, since half of the lesions treated did not change in size from baseline. However, no further studies have corroborated this hypothesis.
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Regorafenib. Regorafenib (Bayer Healthcare, Leverkusen, Germany) is an eye drop multikinase inhibitor (MKI) which targets several angiogenic kinases, including VEGFR-2, VEGFR-1, VEGFR-3, fibroblast growth factor receptor 1 (FGFR1), PDGFR-β and the mutant oncogenic kinases c-KIT, RET and B-RAF. It showed positive results in a phase I clinical trial in healthy volunteers and a phase II clinical trial is currently in progress. 36 -Pan 90806. Pan 90806 (PanOptica) is a MKI of VEGFR-2,
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Integrin receptor antagonists
Integrins are transmembrane proteins that mediate the attachment between cells and the surrounding extracellular matrix. Their ligands are fibronectin, vitronectin, collagen and laminin. 50 Integrins localized at the apical surface of RPE bind to ligands in the interphotoreceptor matrix 51 and participate in the interactions between photoreceptors and the RPE. 52 During aging, the dissociation between the interphotoreceptor matrix and retinal cells seems to contribute to decreasing the supply of oxygen, nutrients and growth factors from the choroidal or retinal vessels, as well as to inhibit the phagocytosis of photoreceptor outer segments. 53 It has been shown that α5β1, αvβ3 and αvβ5 integrins are expressed in CNV tissue, 54 and many studies have demonstrated a possible role for their antagonists in preventing ocular NV. [55] [56] [57] [58] [59] -SM6427. JSM6427 is a small molecule antagonist of the α5β1 integrin, which has been shown to inhibit retinal and CNV in preclinical models. 60 A phase I clinical trial of JSM6427 for nAMD has been completed (ClinicalTrials.gov identifier: NCT00536016). Although encouraging results were obtained, no further studies have evaluated JSM6427. -Volociximab. Volociximab (Ophthotech Corporation, Princeton, NY, USA) is a chimeric monoclonal antibody specifically blocking the binding of fibronectin to the α5β1 integrin. A phase I study evaluating the safety of intravitreal volociximab combined with ranibizumab for nAMD (ClinicalTrials.gov identifier: NCT00782093) revealed good improvements in visual acuity at nine weeks, although the results did not distinguish the independent contributions of ranibizumab and volociximab.
-ALG-1001. ALG-1001, also known as Lu minate (Allegro Ophthalmics, San Juan Capistrano, CA, USA), is a synthetic oligopeptide that targets α5β1, αvβ3 and αvβ5 integrins. It has been investigated for 3 indications: nAMD, diabetic macular edema and vitreomacular traction. In a phase Ib clinical trial ALG-1001 used in combination with ranibizumab for the treatment of nAMD the drug was found to be safe. 61
Anti-inflammatory and antiimmune therapies
Over the last few years many authors have identified inflammatory mechanisms and immune responses as central features in all AMD phenotypes, consolidating the hypothesis that AMD is a singular disease with multiple outcomes. [62] [63] [64] Investigating the role of immune response in the pathogenesis of ocular NV may therefore represent a promising field in the search for new targets for AMD treatments (Figure 2 ). -Infliximab. Tumor necrosis factor alpha (TNF-α) plays a central role in inflammation, apoptosis and immune reactions. The anti-TNF-α monoclonal antibody infliximab (Remicade, Centocor, Inc., Horsham, PA, USA) is commonly used to treat various inflammatory diseases. Intravitreal infliximab has been reported to inhibit laser-induced CNV in rats and has been safely administered up to a dose of 2 mg in the rabbit eye. [65] [66] Intravitreal infliximab was also administered to three patients with nAMD, resulting in improved visual acuity and central foveal thickness on Optical Coherence Tomography (OCT). 67 -POT-4. The alternative complement pathway has also been implicated in the development of AMD. 68 POT-4 is a potent inhibitor of complement factor C3 activation. A phase I clinical trial was designed to evaluate the safety and tolerability of POT-4 administered via intravitreal injections (ClinicalTrials.gov identifier: NCT00473928). Preliminary results indicated that intravitreal POT-4 is safe and well-tolerated and supported its administration in larger randomized clinical trials in order to further define its efficacy profile. Even though no significant improvement in visual acuity was observed, there was no significant visual loss either. 69 -Sirolimus. Mammalian target of rapamy cin (mTOR) is an evolutionarily conserved serine/threonine kinase which appears to function as a central node in a signaling cascade directing the integration of diverse environmental inputs into the immune microenvironment. 70 Sirolimus (previously known as rapamycin, Santen Pharmaceutical, Inc., Osaka, Kapan, and MacuSight, Inc., Union City, CA) was discovered in the 1970s as a soil bacterium metabolite. It was collected on Easter Island (Rapa Nui) and was originally developed as a macrolide antifungal agent. Subsequently, it was found to possess potent immunosuppressive and antiproliferative properties due to its ability to bind to the protein FKBP12. The resulting sirolimus-FKBP12 complex binds 76 A single intrevitreal injection of PF-0523655 ≤3000 mg seemed to be safe and welltolerated in a phase I study involving 27 patients with AMD which had been unresponsive to prior treatment. 77 A phase II clinical trial, the multicenter and randomized MONET study, sought to prove the efficacy of PF-04523655 in combination with Lucentis. It demonstrated the superiority of PF04523655+ranibizumab over ranibizumab monotherapy in terms of best corrected visual acuity improvement. 78 
Connective tissue growth factor inhibition
The 38-KDa cysteine-rich polypeptide connective tissue growth factor (CTGF), which has a pleiotropic and cell type-specific role, was first isolated in human umbilical vein endothelial cells. 79 CTGF is considered to be involved in the pathological synthesis of peri-retinal fibrous tissue in AMD patients. 80 
Tissue factor inhibition
Tissue factor (TF) is expressed in neovascular endothelium but not in the normal vasculature of mouse and pig models. -hI-con1. Factor VII-verteporfin has been tested with the aim of improving the therapeutic results of photodynamic therapy in rats, due to its ability to bind tightly and specifically to TF, which is expressed in the endothelial cells of CNV but not in the normal vasculature. 81 hI-con1 (Iconic Therapeutics Inc. South San Francisco, CA, USA), a synthetic molecule composed of factor VII conjugated to an antibody Fc, binds to TF and selectively destroys pathologic blood vessels. A phase II, randomized, double-masked, multi-center study evaluating the administration of repeated intravitreal injections of hI-con1 in patients with CNV secondary to AMD has recently been completed and the results are pending (ClinicalTrials.gov identifier: NCT02358889).
CD93
Human CD93 is a 652 amino acid surface glycoprotein with a predicted molecular mass of 68 kDa; it is rich in proline and charged amino acids. [82] [83] CD93 expression has been found in several cell types, including the vascular endothelium. [84] [85] Moreover, the soluble EGF-like domain of CD93, which is the product of ectodomain cleavage or shedding, has recently been discovered to be an angiogenic factor. 86 The monoclonal antibody 4E1, binding to CD93, is capable to selectively inhibit blood vessel formation both in vitro and in vivo, without affecting endothelial cell survival. 87 CD93 expression has recently been observed in the endothelial cells of AMDrelated CNV and the soluble CD93 domain has been shown to be overexpressed in the aqueous humor of AMD patients, suggesting that CD93 may represent a potential new antiangiogenic target in the treatment of CNV. 88
HTRA1
HTRA1 is a serine protease involved in protein quality control and cell fate. HTRA1 expression has been found to be significantly higher in CNV patients compared to controls. After treatment with anti-VEGF-A, it returned to control levels. 89 The ability of HTRA1 to regulate extracellular matrix proteoglycan degradation and TGF-β activity appears to allow it to modulate AMD development. [90] [91] HTRA1 can be considered an innovative target. This hypothesis is supported by the discovery of the antibody 94, which is an inhibitor of this protein. 92 
Conclusions
Over the last decade, the management of AMD has changed significantly due to the advent of anti-VEGF-A therapy. However, treatment with anti-VEGF-A agents rarely brings about an improvement in visual acuity. The study of the pathogenetic mechanisms of this disease has led to the discovery of several proteins and factors, which could be used as new molecular targets in AMD therapy.
A great effort has been made to inhibit neoangiogensis with several drugs now in advanced clinical trials (Figure 1 ) targeting new antigens with complementary functions, which could offer novel opportunities to circumvent resistance mechanisms and improve the anti-VEGF-A therapy.
The unsuccessful outcomes of the anti-VEGF-A therapy have often been attributed to development of subretinal fibrosis and inflammatory response. Other interesting drugs seem to come from these fields of research (Figure 2) , with at least four compounds in clinical phase II (Infliximab, Sirolimus, PF-04523655 and hI-con1).
Future directions in AMD treatment will have to focus now on applying combinations of drugs with different angiogenic and non-angiogenic targets, with the aim of achieving disease stabilization or regression, improving visual acuity, and shortening injection intervals. 
